
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
A coalition of pharmacy groups plans to appeal a rejection of its effort to overturn the mandated use of the 5.1 Rx claim standard developed by the National Council for Prescription Drug Programs (NCPDP).






